P

Pfizer

Makes cancer drugs, vaccines and other medicines

Training Manager - Sales Training

Full-TimePosted on 10/28/2026Deadline 11/30/26
No salary listed
Senior
Bachelor's
Bangkok, Thailand
In PersonCandidates should be based in Bangkok.
TrainingCorporate & Technical Training

About the job

Requirements
  • A bachelor's degree is required.
  • At least five years of professional experience, including at least five years in the function or transferable experience.
  • Candidates should be based in Bangkok.
  • Evidence of successful cross-functional and cross-cultural collaboration.
  • A leadership style that positively impacts colleagues at all levels and disciplines.
  • Experience presenting and working at business unit leadership level or regional and global brand team level.
  • A proven track record in change management and strategic leadership, including problem-solving and decision-making that positively impact business results.
  • Strong knowledge of the Thailand pharmaceutical industry and digital trends.
  • Demonstrated training delivery, strong facilitation and collaboration skills, or transferable experience.
  • Strong analytical skills, including analyzing information, synthesizing problems, and developing innovative solutions and strategies.
  • Excellent communication and stakeholder management skills in face-to-face and virtual environments.
  • Proficiency in project management and a proven ability to drive execution of strategies.
  • Proficiency with common technical tools and training platforms.
  • Fluency in Thai and English.
Responsibilities
  • Develop and deliver training that equips customer-facing colleagues to communicate product benefits and Pfizer's pro-innovation and pro-patient approach, supporting broader patient and provider reach and improved patient outcomes.
  • Partner with global, regional, and local stakeholders to address affiliate training needs in line with the EM CET strategy.
  • Drive change and align training practices across EM while maintaining local training service continuity.
  • Represent CET to colleagues and business stakeholders, implementing global strategies in the assigned market.
  • Collaborate with above-market CET teams, the Vietnam/Thailand cluster Commercial team, and local stakeholders.
  • Engage key stakeholders in Thailand or the assigned country, including the Country Manager, Category Lead, Customer Engagement Lead, and People Experience, to consult on organizational learning strategy and priorities.
  • Lead development of the responsible market training plan, ensuring business requirements are met through development and execution of efficient, valued customer-facing colleague training services aligned with Go to Market Excellence.
  • Deliver in-scope training programs, projects, and initiatives that address business needs and priorities; use multiple delivery modalities to deliver programs addressing identified capability needs within budget.
  • Engage Business Unit clients to define and deliver learning initiatives with quantifiable value and impact; work with marketing to understand promotion strategy and incorporate it into training for customer-facing colleagues; coordinate brand training with Medical and Marketing subject matter experts.
  • Deliver live instructor-led learning on varied topics, primarily customer-facing role skills and tools, therapeutic areas, and product knowledge.
  • Establish regular touchpoints to discuss field coaching observations and build and implement appropriate training sustainability solutions.
  • Drive change management of Pfizer ecosystems, tools, and processes, to EM standards with business unit heads and other CLT stakeholders.
  • Use training evaluation tools and partner with the business to discuss training metrics and outcomes and generate insights for continuous improvement.
  • Ensure training content and activities comply with requirements and that the approval system and proper documentation are followed; monitor adherence to streamlined local review and approval of learning materials.
  • Track training interventions using multiple modalities and tools, including face-to-face, virtual, social learning, and micro-learning.
  • Collect and provide country-specific learnings and performance metrics that support continuous improvement.
  • Identify opportunities to streamline training delivery; set performance standards and establish and document a training certification process to ensure trainees are certified in critical capabilities for successful customer-facing interactions.
  • Provide local market insights to global and EM learning strategy teams so global offerings meet complex local requirements.
  • Contribute to development of the training operating plan, agree key training priorities in line with business needs, and secure budget.
  • Secure alignment of local training activities with the EM training strategy.
Desired Qualifications
  • Sales and marketing experience is preferred.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 27th, 2026
AT&T, Pfizer and Zoetis offer yields up to 5.8% with shares under $100

Rising interest rates and bond yields have made dividend stocks less appealing, pushing many lower and their yields higher. Three that trade below $100 are AT&T, Pfizer, and Zoetis, according to The Motley Fool. AT&T trades around $21, down about 16% this year, with a price-to-earnings (P/E) multiple of 11 against 23 for the S&P 500. It yields 5.3% after revenue grew more than 5% in the September quarter. Pfizer trades near $30 and yields 5.8%. Its forward P/E is 10, though its shares are down more than 30% over five years. Zoetis, down 37% this year, trades below $80 with a P/E of 13 and a yield of about 2.6%. Its payout ratio is around 34% of earnings, and it has 12 potential blockbusters in its pipeline.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.